26 Nov

Results of Meeting

Immutep Limited , Level 12, 95 Pitt Street, Sydney NSW 2000 ABN: 90 009 237 889 ASX/Media Release RESULTS OF ANNUAL GENERAL MEETING SYDNEY, AUSTRALIA – 26 Novem ber 2021 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company” ) advises that t he results of its Annual General Meeting (AGM) are set out in th e attached document in accordance with section 251AA ( 2 ) of the Corporations Act 2001 (Cth) and Listing Rule 3.13.2 . P lease be advised that all reso lutions in the Company’s 202 1 Notice of Annual General Meeting were passed by the requisite majorities at today’s AGM . All resolutions were passed and decided by way of poll. A bout Immutep Immutep is a globally active biotechnology company that is a leader in the development of LAG - 3 related immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United S tates. Immutep’s current lead product candidate is eftilagimod alpha (“efti” or “IMP321”), a soluble LAG - 3 fusion protein (LAG - 3Ig), which is a first - in - class antigen presenting cell (APC) activator being explored in cancer and infectious disease. Immute p is also developing an agonist of LAG - 3 (IMP761) for autoimmune disease. Additional LAG - 3 products, including antibodies for immune response modulation, are being developed by Immutep’s large pharmaceutical partners. Further information can be found on the Company’s website www.immutep.com or by contacting: Australian Investors/Media: Catherine Strong, Citadel - MAGNUS +61 (0)406 759 268; cstrong@citadelmagnus.com U.S. Media: Tim McCarthy, LifeSci Advisors +1 (212) 915.2564; tim@lifesciadvisors.com This announcement was authorised for release by Deanne Miller, COO & Company Secretary of Immutep Limited. The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2. Resolution Result If s250U applies Resolution Resolution Type For Against Proxy's Discretion Abstain For Against Abstain For Against Abstain* Carried / Not Carried 274,582,622 1,160,762 1,803,064 843,134 9,845,075 127,337 30,024 286,579,383 1,290,099 873,158 99.55% 0.45% 279,327,851 1,459,484 1,905,023 899,642 20,861,709 3,235 7,443 302,445,205 1,462,719 907,085 99.52% 0.48% 218,401,812 2,041,473 1,659,093 57,037,067 20,373,847 310,667 187,873 240,785,374 2,352,140 57,224,940 99.03% 0.97% 272,208,059 7,149,516 1,855,950 1,628,475 20,026,155 818,873 27,359 294,563,786 7,770,389 1,730,834 97.43% 2.57% 273,775,534 7,596,947 1,865,950 353,569 9,545,972 582,987 2,989,664 285,461,078 8,181,934 3,418,233 97.21% 2.79% 220,099,588 60,109,222 1,583,939 1,799,251 20,036,491 808,537 27,359 242,193,640 60,719,759 1,901,610 79.95% 20.05% 273,727,014 7,591,483 1,521,081 752,422 20,459,980 333,623 78,784 296,058,697 7,925,106 831,206 97.39% 2.61% 279,890,215 1,522,645 1,521,081 658,059 20,505,118 278,855 88,414 302,267,036 1,801,500 746,473 99.41% 0.59% * Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll. Immutep Limited Annual General Meeting Friday, 26 November 2021 Results of Meeting Resolution details Instructions given to validly appointed proxies (as at proxy close) Direct votes (as at close of direct voting) Number of votes cast on the poll (where applicable) 1. Adoption of Remuneration Report Ordinary Carried No 2. Re-election of Director - Dr Russell Howard Ordinary Carried NA 3. Ratification of previous Share issue Ordinary Carried NA 4. Approval of grant of performance rights to Dr Russell Howard Ordinary Carried NA 5. Approval of the use of performance rights and/or options under the Company's Executive Incentive Plan Ordinary Carried NA 6. Approval of grant of performance rights to Mr Marc Voigt Ordinary Carried NA 7. Approval of Amendment to Constitution Special Carried NA 8. Approval of Proportional Takeover Provisions Special Carried NA
Information on this Website is provided for general information purposes only and is not a substitute for professional advice. ASX Information (including company announcements and prices) is delayed by at least 20 minutes. JSE Information (including company announcements and prices) is delayed by at least 15 minutes. Reliance on the information you access on or from this Website is solely at your own risk. We make no representation or warranty in relation to the future performance of the companies that appear on this Website. Investment in securities involves risk and you should obtain independent professional legal, financial, investment or company advice before acting on any of the information you access on this Website. Using, browsing or otherwise accessing this Website is subject to our Terms and Conditions and our Privacy Policy.

© 2021 Listcorp. ABN 60 166 140 307

Never miss news from Immutep Limited (ASX:IMM) when you join Listcorp.